Keywords
How to Cite
Abstract
The difficulty to obtain greater survival in patients
with acute myeloid leukemia (AML), despite the
improvement in the management of complications
and the deeper knowledge of molecular alterations,
forces us to pay attention to their characteristics and treatment. The objective was to evaluate cytogenetic, molecular aspects and global survival of patients with AML treated in a tertiary hospital in the Mendoza province. An observational, comparative and retrospective study was conducted and 22 cases of AML attended between 2010-2017 were included. General characteristics: mean age 49,4 (± 17,6) years, female gender 54,5%, de novo origin 19 (86,4%) and intermediate risk 10 (58,8%). They received induction (7 + 3): 17 (77,3%), reached complete remission 8 (47,1%) and partial remission 5 (29,4%). They had post-consolidation relapse 10 (76,9%). The global survival was 10 months (3- 17). The survival discriminated by risk was: low 7 months, intermediate 11,5 (5-24,5) and high 3 (0-3). The global mortality was 16 (72,7%). The response to the induction treatment was the independent survival variable p=0,01 (95%CI 0,001-0,42), in the multivariate model. In our sample, AML predominated in women, de novo origin, intermediate risk and the global mortality was high. Half of the patients had complete post-induction remission, which was associated with a longer survival.
References
2017.asp en Octubre 2017.
2. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer Journal. 2016 Jul 1;6(7):e441.
3. Suarez Beyríes L, Carnot Uría J, Arenas R y col. Leucemias agudas en pacientes mayores de 60 años. Rev
Cubana Med. 2003;42:18-26.
4. Dupont J. Leucemia mieloblástica aguda en Argentina: progresando. Hematología. 2017;21:31-33.
5. Hagop M, Kantarjian X, Thomas A y col. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine
Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2012;30:2670-2677.
6. Mela Osorio MJ, Gimenez Conca AD, Dick H y col. Evaluación clínica y de respuesta al tratamiento de pacientes con leucemia mieloide aguda. Estudio multicéntrico. Hematología. 2017;21:8-14.
7. Kottaridis P, Gale R, Frew M y col. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML10 and 12 trials. Blood. 2001;98:1752-1759.
8. Giménez Conca A, Arbelbide J, Schutz N y col. Variables condicionantes del tratamiento en pacientes añosos con leucemia mieloide aguda. Experiencia institucional. Medicina. 2016;76: 81-88.
9. Duque-Sierra L, Restrepo-Perdomo C, Zapata-Cárdenas A y col. Características morfológicas, citogenéticas e inmunofenotípicas de pacientes con leucemia mieloide aguda. Medellín, Colombia. Cimel. 2006;11:72-77.
10. Döhner H, Estey E, Amadori S. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115:453-474.
11. Sierra J. La genética como guía del manejo de la leucemia mieloide aguda. Hematología. 2015;19:81-86.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar